Novozymes completes acquisition of Microbiome Labs

Novozymes A/S has completed the acquisition of Microbiome Labs following the fulfillment of all closing conditions. The acquisition was initially announced on December 18, 2020, in company announcement number 65/2020. Microbiome Labs will now be integrated into Novozymes’ human health activities as part of the OneHealth platform and sales will be reported in the Food, Beverages & Human Health segment.

About Novozymes OneHealth
Novozymes has established the OneHealth platform to focus on human health applications within oral and gut health. The ambition for OneHealth is to leverage Novozymes’ strong scientific capabilities and ability to combine probiotics with enzymes to develop innovative, effective, and clinically-proven solutions that improve human health and well-being. Please refer to www.novozymesonehealth.com for more information.

About Microbiome Labs
Microbiome Labs was founded in 2012, employs 80 people, and is based in Glenview, Illinois. The company has an attractive position in the North American probiotics market with a comprehensive suite of proprietary probiotic and microbiome solutions targeting gastrointestinal, immune, metabolic, and cognitive health. Please refer to www.microbiomelabs.com for more information.

Contact information

Investor Relations
Tobias Bjorklund  
+45 3077 8682  
tobb@novozymes.com
Carl Ahlgren  
+1 919 702 6144  
cxl@novozymes.com
Ulrik Wu Sware  
+45 3077 3187  
ulms@novozymes.com

Media Relations
Lina Danstrup  
+45 3077 0552  
likr@novozymes.com